Drug intelligence / Profile preview

ASC-201

Development stage: Unknown
Lead developer: Ascelia Pharma
Modality: Small Molecules
Administration: Oral

Overview

ASC-201 (Oncoral) is an investigational oral formulation of irinotecan, a topoisomerase I inhibitor, being developed by Ascelia Pharma. Irinotecan is a camptothecin derivative that inhibits DNA topoisomerase I, leading to double-strand DNA breaks and cell death. While irinotecan is traditionally administered intravenously, ASC-201 is designed as a small-molecule oral tablet to improve patient convenience and potentially offer a better safety profile through different dosing schedules. It is primarily being evaluated for the treatment of advanced gastric cancer, particularly in the third-line setting, often in combination with other agents like trifluridine/tipiracil (Lonsurf).

Brand names: Oncoral
Other names: oral irinotecan

Targets

TOP1 (DNA Topoisomerase I)HIF1A (Hypoxia-inducible factor 1-alpha)

Beyond the preview

Go deeper on ASC-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC-201.

Explore the full profile